CG Oncology, Inc. Common stock (CGON)vsEli Lilly and Company (LLY)
CGON
CG Oncology, Inc. Common stock
$72.35
+0.49%
HEALTHCARE · Cap: $6.38B
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1279059% more annual revenue ($79.67B vs $6.23M). LLY leads profitability with a 33.5% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
CGON
Avoid32
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 1983.0% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -17.1% — below average capital efficiency
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : CGON
The strongest argument for CGON centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 1983.0% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : CGON
The primary concerns for CGON are EPS Growth, Profit Margin, Piotroski F-Score.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
CGON profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.50 — expect wider price swings.
CGON is growing revenue faster at 1983.0% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 32/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CG Oncology, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070, an oncolytic virus therapy designed for non-muscle invasive bladder cancer. The company is well-positioned to meet significant unmet medical needs in oncology, emphasizing the potential to improve patient outcomes and transform treatment approaches. With a robust proprietary technology platform and a commitment to advancing clinical trials and securing regulatory approvals, CG Oncology represents a compelling investment opportunity for institutional investors interested in pioneering advancements in cancer care.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?